Imexpharm Corporation (HOSE:IMP)

Vietnam flag Vietnam · Delayed Price · Currency is VND
54,000
+100 (0.19%)
At close: Feb 27, 2026
12.50%
Market Cap 8.32T
Revenue (ttm) 2.44T
Net Income (ttm) 304.39B
Shares Out 154.01M
EPS (ttm) 1,976.44
PE Ratio 27.32
Forward PE 22.65
Dividend 500.00 (0.93%)
Ex-Dividend Date Jun 9, 2025
Volume 44,747
Average Volume 34,255
Open 53,900
Previous Close 53,900
Day's Range 53,900 - 54,200
52-Week Range 36,100 - 56,500
Beta 0.69
RSI 60.08
Earnings Date Jan 16, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. The company was founded in 1997 and is headquartered in Cao Lãnh, Vietnam. [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 1,456
Stock Exchange Ho Chi Minh Stock Exchange
Ticker Symbol IMP
Full Company Profile

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 2.30%.

Financial Statements

News

There is no news available yet.